cylindrin: erythrocyte membrane protein which contains two predominant polypeptide chains of 22,500 & 28,000 MW with smaller quantity of a 25,500 MW band; do not confuse with cylindrin in Chemline, a synonym for isoarborinol methyl ether [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 189045 |
| CHEBI ID | 81166 |
| SCHEMBL ID | 3679265 |
| MeSH ID | M0097776 |
| Synonym |
|---|
| 17904-55-1 |
| cylindrin |
| C17534 |
| (3s,3as,5as,5bs,7ar,9s,11as,13ar,13bs)-9-methoxy-3a,5a,8,8,11a,13a-hexamethyl-3-propan-2-yl-1,2,3,4,5,5b,6,7,7a,9,10,11,13,13b-tetradecahydrocyclopenta[a]chrysene |
| d:c-friedo-b':a'-neogammacer-9(11)-ene, 3-methoxy-, (3beta,8beta,13beta,14alpha,17beta,18alpha,21beta)- |
| SCHEMBL3679265 |
| CHEBI:81166 |
| Q-100936 |
| Q27155121 |
| 9-methoxy-3a,5a,8,8,11a,13a-hexamethyl-3-(propan-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,13,13a,13b-octadecahydro-1h-cyclopenta[a]chrysene |
| DTXSID30939172 |
| HY-121227 |
| CS-0081264 |
| AKOS040745691 |
Cylindrin is a six-stranded antiparallel beta barrel obtained from amyloidogenic strands of crystallin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cylindrin is a six-stranded antiparallel beta barrel obtained from amyloidogenic strands of crystallin. " | ( Comparative modeling of hypothetical amyloid pores based on cylindrin. Kotulska, M; Zulpo, M, 2015) | 2.1 |
| Class | Description |
|---|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||